Study of autoimmune polyglandular disease genetics in Taiwan
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study looks at how common autoimmune polyglandular syndrome type II is in Taiwan and what genetic differences may be involved. It uses past hospital visit records and focuses on people who had a specific pattern of autoimmune conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have visited National Taiwan University Hospital (NTUH) sometime from 2006 to 2021
- You must have at least two of these three conditions: type 1 diabetes, primary adrenal insufficiency, or autoimmune thyroid disease
- You must be 20 years old or older
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry study collects health information from people with diabetes to help researchers better understand and improve diabetes care in Taiwan. It involves no new treatments or procedures.
This study collects and uses information from people who have Sjögren’s syndrome and/or dry eye and some inflammation-related conditions. It may help researchers better understand these illnesses and how they relate to each other in the Taiwanese population.
This study looks at chemical differences in the body between people with metabolic syndrome and healthy people. It may help find better ways to diagnose or treat metabolic syndrome.
This study checks if people with autoimmune thyroid disease may also be at risk for developing type 1 diabetes. It looks at the body's attack on insulin-producing cells in the pancreas, using blood tests to catch early signs.
This study follows people with autoimmune hepatitis (a condition where the immune system attacks the liver) and requires key blood test results at diagnosis. It may help doctors better understand this disease and how it progresses in patients in China.
This study follows people who have islet autoantibodies (markers in the blood that can increase the risk of type 1 diabetes) but do not have diabetes yet. The goal is to better understand how these antibodies affect health over time.
Hear when a new Autoimmune Polyendocrine Syndrome Type II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.